Apremilast
- TRADE NAME: Otezla (Celgene)
- INDICATIONS: Psoriatic arthritis, plaque psoriasis
- CLASS: Antipsoriatic agent, Phosphodiesterase inhibitor, Phosphodiesterase type 4 (PDE4) inhibitor
- HALF-LIFE: 6–9 hours
FDA APPROVAL DATE: 03/21/2014
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Carbamazepine, Phenobarbital, Phenytoin, Rifampin
PREGNANCY CATEGORY: C
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of apremilast in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 10/19/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric